GILD Gilead Sciences, Inc.

Price (delayed)

$68.5

Market cap

$85.92B

P/E Ratio

17.52

Dividend/share

$2.62

EPS

$3.91

Enterprise value

$99.97B

Sector: Healthcare
Industry: Drug Manufacturers - General
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Highlights

GILD's P/E is 11% below its last 4 quarters average of 19.7
Gilead Sciences's debt has decreased by 9% YoY and by 2% QoQ
The quick ratio has contracted by 16% YoY and by 2.8% from the previous quarter
The company's net income fell by 16% YoY and by 8% QoQ

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$85.92B
Enterprise value
$99.97B
Valuations
Price to earnings (P/E)
17.52
Price to book (P/B)
3.92
Price to sales (P/S)
3.81
EV/EBIT
17.17
EV/EBITDA
13.85
EV/Sales
4.4
Earnings
Revenue
$22.72B
EBIT
$5.82B
EBITDA
$7.22B
Free cash flow
$8.38B
Per share
EPS
$3.91
Free cash flow per share
$6.64
Book value per share
$17.46
Revenue per share
$18
TBVPS
$33.38
Balance sheet
Total assets
$59.74B
Total liabilities
$37.56B
Debt
$24.1B
Equity
$22.07B
Working capital
$18.07B
Liquidity
Debt to equity
1.09
Current ratio
3.04
Quick ratio
2.78
Net debt/EBITDA
1.95
Margins
EBITDA margin
31.8%
Gross margin
79.4%
Net margin
21.8%
Operating margin
19.6%
Efficiency
Return on assets
8.1%
Return on equity
22.6%
Return on invested capital
12.3%
Return on capital employed
11.4%
Return on sales
25.6%
Dividend
Dividend yield
3.82%
DPS
$2.62
Payout ratio
67%

GILD stock price

How has the Gilead Sciences stock price performed over time

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$22.72B
Gross profit
$18.03B
Operating income
$4.45B
Net income
$4.96B
Gross margin
79.4%
Net margin
21.8%
The operating margin has contracted by 47% YoY but it has grown by 2.6% from the previous quarter
The operating income has declined by 46% year-on-year but it has grown by 3.8% since the previous quarter
Gilead Sciences's net margin has decreased by 17% YoY and by 9% QoQ
The company's net income fell by 16% YoY and by 8% QoQ

Valuation

What is Gilead Sciences stock price valuation
P/E
17.52
P/B
3.92
P/S
3.81
EV/EBIT
17.17
EV/EBITDA
13.85
EV/Sales
4.4
GILD's EPS is down by 15% year-on-year and by 8% since the previous quarter
GILD's P/E is 11% below its last 4 quarters average of 19.7
The stock's price to book (P/B) is 23% less than its 5-year quarterly average of 5.1
Gilead Sciences's equity has decreased by 2% from the previous quarter

Efficiency

How efficient is Gilead Sciences business performance
Gilead Sciences's ROIC has decreased by 39% YoY and by 8% from the previous quarter
GILD's return on sales is down by 38% year-on-year and by 7% since the previous quarter
The company's return on equity fell by 16% YoY and by 8% QoQ
GILD's return on assets is down by 12% year-on-year and by 7% since the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.62
Dividend yield
3.82%
Payout ratio
67%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 59% higher than its total liabilities
The quick ratio has contracted by 16% YoY and by 2.8% from the previous quarter
The total liabilities has contracted by 8% YoY and by 3.6% from the previous quarter
Gilead Sciences's debt is 9% higher than its equity
Gilead Sciences's debt has decreased by 9% YoY and by 2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.